SAN DIEGO, Sept. 8, 2015 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), a clinical stage oncology company developing new treatments for cancer and associated pain, announced that Dr. Henry Ji, President and Chief Executive Officer, will be presenting at several upcoming conferences:
Event: | Rodman & Renshaw 17th Annual Global Investment Conference | |
Date: | Wednesday, September 9, 2015 | |
Time: | 4:15 to 4:40 p.m., EDT | |
Location: | Fontainebleau Room (2nd floor), The St. Regis Hotel, New York, NY | |
Event: | BioCentury NewsMakers in the Biotech Industry | |
Date: | Thursday, September 10, 2015 | |
Time: | 9:30 to 9:55 a.m., EDT | |
Location: | Room 311; Millennium Broadway Hotel & Conference Center, New York, NY |
About Sorrento Therapeutics, Inc.
Sorrento is a clinical stage biopharmaceutical company developing new treatments for cancer and associated pain and inflammation and autoimmune diseases. Sorrento recently licensed multiple late-stage biosimilar and biobetter antibodies for oncology and inflammation diseases for the US, European and Japanese markets. Sorrento recently sold the rights to Cynviloq, which successfully completed the TRIBECA study, to NantPharma. The company is also developing resiniferatoxin (RTX), a non-opiate TRPV1 agonist to treat terminal cancer patients suffering from intractable pain.
In December 2014, Sorrento and NantWorks formed a global joint venture, now called Immunotherapy NANTiBody, LLC, to focus on immunotherapies for cancer. Also in December 2014, Sorrento and Conkwest, Inc., now renamed as NantKwest, Inc., an immuno-oncology company developing proprietary Neukoplast®, a Natural Killer (NK) cell-line based therapy, entered into an agreement to jointly develop CAR.TNK (Chimeric Antigen Receptor Tumor-attacking Neukoplast) immunotherapies for the treatment of cancer and infectious diseases. In March 2015, Sorrento entered into a global collaboration with NantCell, a NantWorks company, to discover and develop immunotherapies against tumor neo-epitopes. In July 2015, Sorrento and NantBioScience, Inc., a subsidiary of NantWorks, established a joint venture, called NantCancerStemCell, LLC to focus on the development of "first-in-class" small molecules against targets which may address important drivers of cancer growth including cancer stem cells.
Sorrento, G-MAB, CAR.TNK, TNK Therapeutics, and the Sorrento logo are trademarks owned by Sorrento Therapeutics, Inc.
All other trademarks and trade names are the property of their respective owners.
© 2015 Sorrento Therapeutics
Logo - http://photos.prnewswire.com/prnh/20150105/167173LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sorrento-to-present-at-upcoming-conferences-300139168.html
SOURCE Sorrento Therapeutics, Inc.
Help employers find you! Check out all the jobs and post your resume.
